Table 2. Correlation between KRAS mutational status in tumor tissues and CTC.
| KRAS CTC wild-type mutated | Total | ||
|---|---|---|---|
| KRAS tissue wild-type count | 13 | 4 | 17 |
| % within KRAS tissue | 76.5% | 23.5% | 100.0% |
| % within KRAS tissue | 54.2% | 66.7% | 56.7% |
| % of total | 43.3% | 13.3% | 56.7% |
| Mutated count | 11 | 2 | 13 |
| % within KRAS tissue | 84.6% | 15.4% | 100% |
| % within KRAS tissue | 45.8% | 33.3% | 43.3% |
| % of total | 36.7% | 6.7% | 43.3% |
| Total count | 24 | 6 | 30 |
| % within KRAS tissue | 80.0% | 20.0% | 100.0% |
| % within KRAS tissue | 100.0% | 100.0% | 100.0% |
| % of total | 80.0% | 20.0% | 100.0% |